Device Trial Radar · NCT07008001
Assessment of DOT Spectacles in Chinese Children Extension
Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
175
Planned (sponsor's estimate)
Start
Aug 1, 2025
Primary completion
Dec 31, 2026
Study completion Jun 30, 2027
Sponsor
- Lead sponsor
- SightGlass Vision, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jun 6, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 8 years, up to 16 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.
Conditions
- Juvenile Myopia
- Myopia
Interventions
Novel spectacle lens designDevice
Use of spectacle lenses may reduce the rate of progression of juvenile myopia
Primary outcomes
What the sponsor says the trial is designed to measure.
- Axial length Group ITime frame: 12 months
- Axial length Group IITime frame: 12 months
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
Aier Eye Hospital
Changsha, China
West China Hospital
Chengdu, China
Zhongshan Ophthalmic Center
Guangzhou, China
2 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.